Document is current
Any future updates will be listed below
-
Authors
Balood, Mohammad
Ahmadi, Maryam
Eichwald, Tuany
Ahmadi, Ali
Majdoubi, Abdelilah
Roversi, Karine
Roversi, Katiane
Lucido, Christopher T.
Restaino, Anthony C. https://orcid.org/0000-0002-5562-2670
Huang, Siyi
Ji, Lexiang
Huang, Kai-Chih
Semerena, Elise https://orcid.org/0000-0002-8954-6274
Thomas, Sini C.
Trevino, Alexandro E.
Merrison, Hannah
Parrin, Alexandre
Doyle, Benjamin
Vermeer, Daniel W.
Spanos, William C. https://orcid.org/0000-0002-7975-1151
Williamson, Caitlin S.
Seehus, Corey R.
Foster, Simmie L.
Dai, Hongyue
Shu, Chengyi J.
Rangachari, Manu
Thibodeau, Jacques
V. Del Rincon, Sonia
Drapkin, Ronny https://orcid.org/0000-0002-6912-6977
Rafei, Moutih
Ghasemlou, Nader https://orcid.org/0000-0002-1696-7342
Vermeer, Paola D. https://orcid.org/0000-0003-2370-8223
Woolf, Clifford J. https://orcid.org/0000-0002-6636-3897
Talbot, Sebastien
- License Information
-
More Information
Article History
Received: 9 June 2021
Accepted: 21 September 2022
First Online: 2 November 2022
Competing interests
: S.T. and C.J.W. have an equity stake in Nocion Therapeutics. S.T. and C.J.W. have deposited a provisional patent (WO 2021/173916) on the use of charged sodium channel blockers to silence nociceptor neurons as a means to safeguard host anti-tumour immunity.
